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BACKGROUND: This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic
non-pancreatic neuroendocrine tumours (NETs).
METHODS: Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1–14 of 3-week cycles.
RESULTS: Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue.
CONCLUSION: The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management
of NETs.
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Neuroendocrine tumours (NETs) arise from secretory cells in the
nervous and endocrine systems that often present with symptoms
related to the excess production of hormones, neuropeptides and
neurotransmitters (Oberg and Jelic, 2009). The incidence increased
from 1.1 to 5.2 cases per 100000 between 1973 and 2004, in part
reflecting better detection and diagnosis (Yao et al, 2008).
For unresectable tumours, the choice of treatment is determined
by the anatomical origin, degree of differentiation and endocrine
function of the NET (Plockinger, 2007; Modlin et al, 2008; Clark
et al, 2009). Therapeutic options include somatostatin analogues,
targeted radiotherapy, immunotherapy (interferon-a (IFN-a)),
hepatic artery embolisation, radiofrequency ablation, cytotoxic
chemotherapy and agents that target mTOR or angiogenesis
(Modlin et al, 2008; Basu et al, 2010). For patients with advanced
pancreatic NETs, streptozotocin (STZ)-based chemotherapy
regimens are the standard of care (Moertel et al, 1992).
Streptozotocin-based therapy also has a role in the treatment of
non-pancreatic NETs, although these tumours tend to be less
sensitive. The pyrimidine analogue 5-Fluorouracil (5FU) is often
used in combination with STZ (Basu et al, 2010), but toxicity
remains an issue, highlighting the need to improve tolerability
without affecting efficacy.
Treatment of colorectal cancer (CRC) with capecitabine, the
orally administered pro-drug of 5FU, results in better clinical
benefit compared with bolus 5FU (Hoff et al, 2001; Cassidy et al,
2002). Meta-analysis has demonstrated increased response rates
following prolonged administration of 5FU compared with bolus
5FU (Meta-analysis Group in Cancer, 1998). In NETs, infusional
5FU combined with IFNa resulted in clinical activity and good
tolerability (Andreyev et al, 1995). We report here the results of a
study of capecitabine monotherapy in metastatic non-pancreatic
NETs. Our aims were to evaluate the tolerability, clinical outcome
and to establish the rationale for using capecitabine in combina-
tion therapy as an alternative to infusional 5FU in NETs.
PATIENTS AND METHODS
This was an open-label, multi-centre, single arm, phase II study.
Patients received oral capecitabine 2000mgm
 2 per day adminis-
tered in two divided doses for 14 consecutive days every 3 weeks.
Patients with Xgrade II NCI-CTC toxicity had treatment withheld
until toxicity returned to pgrade I. For second and third
occurrences of grade II, and first or second episodes of grade III,
toxicity doses were reduced by 25 and 50%, respectively.
Treatment was discontinued in cases of subsequent toxicity or
disease progression. Baseline evaluations included: complete
medical history, physical and radiological examinations, full blood
count, biochemistry, Chromogranin A and urinary 5-HIAA.
Toxicity was evaluated every 3 weeks. Response was evaluated
every 9 weeks according to RECIST criteria. Biochemical responses
were defined as: complete response (CR), return of both markers
to normal; partial response (PR), 450% decrease from baseline;
stable disease (SD), o50% decrease and o25% increase from the
baseline; progressive disease (PD), 425% increase from the
baseline. Overall response was defined as either the best
radiological or biochemical response obtained.
Adult patients with a histological diagnosis of inoperable, locally
advanced or metastatic NET were eligible for inclusion if they had:
Received 4 August 2010; revised 13 January 2011; accepted 9 February
2011; published online 8 March 2011
*Correspondence: Dr DC Talbot; E-mail: denis.talbot@medonc.ox.ac.uk
British Journal of Cancer (2011) 104, 1067–1070
















sbiochemically or radiologically measurable disease, an ECOG
performance status of 0–2, adequate organ function (white
blood cells X3 10
9l





 1, bilirubin p30mmoll
 1, creatinine p150mmoll
 1)
and life expectancy of at least 3 months. Patients with stable
disease on octreotide therapy before study entry were allowed to
continue octreotide. Patients were excluded if they had a diagnosis
of pancreatic NET, Ki6742%, had received previous chemo-
therapy, previous malignancy or uncontrolled systemic disease.
Local Research Ethics Committees approved the study and written
informed consent was obtained from all patients. The study was
carried out in accordance with Good Clinical Practice.
Statistical considerations
Gehan’s two-stage design was adopted in this study to allow for the
early rejection of an ineffective drug. The target patient accrual for
the first stage was 19 patients with additional patients recruited
depending on response rate such that if capecitabine were active in
more than 15% of patients then the probability of it being rejected
erroneously would have been 0.046 (Gehan, 1961). Changes in the
severity of diarrhoea were analysed by comparing baseline levels
with those of each subsequent cycle using the Stuart–Maxwell test.
Overall survival was estimated using the Kaplan–Meier method.
RESULTS
A total of 20 patients were recruited between three sites in the UK
(Oxford, Glasgow, Cheltenham) and followed up for a median of
27 months. One patient was replaced because of non-compliance
with the study protocol. In total, 19 patients (demographics shown
in Table 1) completed at least one cycle of treatment and were
assessable for response and safety evaluation. Two patients remain
on study, 4 years after enrolment.
Capecitabine was generally well tolerated (Table 2). Single
episodes of grade IV toxicity were recorded for infection, raised
liver function tests (LFT’s), thrombocytopenia, leucopenia and
neutropenia. The most common grade III toxicities were diarrhoea
(26% patients), fatigue (21% patients) and raised LFTs (21%
patients). Most patients, as expected, experienced a rash and/or
hand-foot syndrome (HFS), but all were of grade I-II toxicity. The
Stuart–Maxwell test showed no statistically significant increase in
the grade of diarrhoea between baseline and subsequent cycles of
capecitabine therapy.
A total of 13 (68%) patients achieved a radiological SD of whom
two (11%) also had biochemical PR by Chromogranin A. Three
(16%) patients had radiological PD and three (16%) were not
evaluable radiologically. There were no radiological PR or CR, thus
the overall disease control rate was 68%. Four (21%) patients
maintained SD for 412 months. Of these, two remain well in the
follow-up phase of study and two discontinued treatment because
of toxicity. Overall seven patients came off study due to PD (37%),
five due to toxicity (26%), three by patient choice and two by
investigator choice. The investigators’ reason in both cases was to
defer treatment until symptomatic disease progression.
The median PFS was 9.9 months (lower quartile: 4.4, upper
quartile: 36.7) and median OS was 36.5 months (lower quartile:
19.9, upper quartile not yet reached).
DISCUSSION
We report that capecitabine monotherapy in metastatic
non-pancreatic NETs is safe and well tolerated. The toxicity
experienced was similar to that reported in CRC (Hoff et al, 2001;
Cassidy et al, 2002; Saif et al, 2008). We observed lower grades of
HFS in patients with NETs compared with CRC and diarrhoea,
both a feature of carcinoid syndrome and capecitabine toxicity,
Table 1 Patient characteristics
Characteristic No. of patients (%)
Total evaluable 19







Not recorded/available 2 (11)





Not started 11 (58)
Started before study entry 8 (42)
Site of metastasis at diagnosis (six patients had liver only metastasis,
11 multiple metastatic sites)
Liver 14










Table 2 Toxicity profile








Hand-foot syndrome 0 (0)
Cough 0 (0)
Rash 0 (0)



















Abbreviation: LFT¼liver function test.
aOne of these was grade IV.
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swas not significantly exacerbated compared with baseline.
Higher rates of grade III–IV diarrhoea were observed in this
study relative to studies of capecitabine in CRC (Cassidy et al,
2002; Saif et al, 2008), which may be disease related. In CRC, there
are clinically significant differences in the tolerability of cape-
citabine over bolus 5FU (Meta-analysis Group in Cancer, 1998;
Hoff et al, 2001). Although uncomplicated hyperbilirubinemia and
HFS occur more frequently with capecitabine, patients benefit
from decreased rates of stomatitis, alopecia, neutropenia and
neutropenic fever and sepsis (Van Cutsem et al, 2001; Cassidy
et al, 2002). Moreover, in rectal cancer, capecitabine had superior
or equivalent efficacy to metronomic 5FU infusion (Das et al, 2005;
Saif et al, 2008). We show that capecitabine has an acceptable
safety profile in non-pancreatic NETs justifying its inclusion in
current and novel combination regimens as a substitute for
conventional infusional 5FU.
Our study excluded patients for whom combination chemo-
therapy was indicated thus high-response rates were not antici-
pated for this group of patients. Of three patients who had received
octreotide for over 12 months before entry to the study two had
stable disease following capecitabine that may have been the effect
of ongoing octreotide therapy (Brizzi et al, 2009; Rinke et al, 2009).
Although the study was designed to detect inactivity, it was not
powered sufficiently to confirm efficacy. Thus, we can conclude
that the disease control rate of 68%, two biochemical PRs and
median OS of 36.5 months in this study only suggest that
capecitabine may have antitumour activity in non-pancreatic
NETs. These findings should be considered in the light of the
PROMID Study (Rinke et al, 2009) that reported a 6 months
(95% CI, 3.7–9.4 months) median time to tumour progression in
the placebo-treated group. A randomised placebo-controlled trial
including an octreotide treatment arm would be required to test
this hypothesis.
Neuroendocrine tumours do not overexpress thymidine phos-
phorylase (TP), a key enzyme in activation of capecitabine to 5FU
(Ishikawa et al, 1998). However, expression of thymidylate
synthase (TS), an enzyme targeted by 5FU, is increased in poorly
differentiated NETs (Ceppi et al, 2008). Infusional 5FU and oral
agents, which give similar continuous exposure are thought to
exert antitumour effect through TS inhibition, as opposed to short
exposure to bolus 5FU, which targets RNA synthesis (Aschele et al,
1992). This strengthens the rationale for the use of infusional or
continuous oral treatment schedules in NET therapy.
We have demonstrated the safety and tolerability of capecitabine
in the setting of advanced non-pancreatic NETs. This study
provides the rationale for inclusion of capecitabine in the UK
NETwork randomised phase II trial comparing capecitabineþSTZ
with capecitabineþSTZþcisplatin in patients with advanced
NETs.
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